Company Website: http://www.invivotherapeutics.com
CAMBRIDGE, Mass. -- (Business Wire)

InVivo Therapeutics Holdings Corp. (NVIV) today announced that Mark Perrin, Chief Executive Officer and Chairman, is scheduled to present at Cantor Fitzgerald’s Inaugural Healthcare Conference to be held Wednesday, July 8, 2015 at Le Parker Méridien Hotel in New York City, NY. The company’s presentation will be at 10:45 A.M. (EDT).

Mr. Perrin said, “I am pleased to be presenting at Cantor’s Inaugural Healthcare Conference. This presentation opportunity is part of our larger communications effort to inform investors and other key constituencies of the significant progress the company has achieved to establish our leadership role in the spinal cord injury market.”

Additional information about the conference can be found at http://www.cantorconferences.com/health-overview.

About the Neuro-Spinal Scaffold

Following an acute spinal cord injury, the biodegradable Neuro-Spinal Scaffold is surgically implanted at the epicenter of the wound and is designed to act as a physical substrate for nerve sprouting. Appositional healing to spare spinal cord tissue, decreased post-traumatic cyst formation, and decreased spinal cord tissue pressure have been demonstrated in preclinical models of spinal cord contusion injury. The Neuro-Spinal Scaffold, an investigational device, has received a Humanitarian Use Device (HUD) designation and is currently being studied in an Investigational Device Exemption (IDE) pilot study for the treatment of patients with complete (AIS A) traumatic acute spinal cord injury.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company’s investigational Neuro-Spinal Scaffold received the 2015 Becker’s Healthcare Spine Device Award. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150701005085/en/

Contacts:

InVivo Therapeutics Holdings Corp.
Brian Luque, 617-863-5535
Investor Relations
bluque@invivotherapeutics.com

Source: InVivo Therapeutics Holdings Corp.